Literature DB >> 10454613

Inhibition of luciferase expression by synthetic hammerhead ribozymes and their cellular uptake.

B Bramlage1, S Alefelder, P Marschall, F Eckstein.   

Abstract

Two synthetic hammerhead ribozymes, one unmodified and the other with 2"-modifications and four phosphorothioate groups, targeting a single GUA site in the luciferase mRNA, were compared for their inhibition of gene expression in cell cultureand their cellular uptake was also analysed. A HeLa X1/5 cell line stably expressing luciferase, under an inducible promoter, was treated with these ribozymes by liposome-mediated transfection to determine their activity. Luciferase expression in cells was inhibited to approximately 50% with little difference between the unmodified and the 2"-modified ribozyme. A similar degree of inhibition was observed with two catalytically inactive ribozymes, indicating that inhibition was mainly due to an antisense effect. A ribozyme carrying a cholesterol moiety, applied to the cells without carrier, showed no inhibition. Northern blotting indicated a similar amount of cellular uptake of all ribozymes. The unmodified ribozyme was essentially evenly distributed between cytoplasm and nucleus, whereas a higher proportion of the phosphorothioate-containing ribozyme was observed in the nucleus. Fluorescence microscopy, including confocal microscopy using 5"-fluorescein-labelled ribozymes, showed that the unmodified and 2"-modified ribozymes were present in the cytoplasm and in the nucleus to a similar extent, whereas the fluorescence of the phosphorothioate-containing ribozyme was much stronger in the nucleus. Both ribozymes inhibited luciferase expression to a comparable degree, suggesting that the ribozyme in the nucleus did not contribute significantly to the inhibition. Ribozymes with a cholesterol moiety were predominantly trapped in the cell membrane, explaining their inability to interfere with gene expression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10454613      PMCID: PMC148543          DOI: 10.1093/nar/27.15.3159

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  44 in total

1.  Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.

Authors:  M Gossen; H Bujard
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

2.  Inhibition of Plasmodium falciparum proliferation in vitro by ribozymes.

Authors:  M V Flores; D Atkins; D Wade; W J O'Sullivan; T S Stewart
Journal:  J Biol Chem       Date:  1997-07-04       Impact factor: 5.157

3.  The subcellular localization and length of hammerhead ribozymes determine efficacy in human cells.

Authors:  R Hormes; M Homann; I Oelze; P Marschall; M Tabler; F Eckstein; G Sczakiel
Journal:  Nucleic Acids Res       Date:  1997-02-15       Impact factor: 16.971

4.  Use of a hammerhead ribozyme with cationic liposomes to reduce leukocyte type 12-lipoxygenase expression in vascular smooth muscle.

Authors:  J L Gu; J Nadler; J Rossi
Journal:  Mol Cell Biochem       Date:  1997-07       Impact factor: 3.396

5.  High activity and stability of hammerhead ribozymes containing 2'-modified pyrimidine nucleosides and phosphorothioates.

Authors:  O Heidenreich; F Benseler; A Fahrenholz; F Eckstein
Journal:  J Biol Chem       Date:  1994-01-21       Impact factor: 5.157

6.  Nuclease-resistant ribozymes decrease stromelysin mRNA levels in rabbit synovium following exogenous delivery to the knee joint.

Authors:  C M Flory; P A Pavco; T C Jarvis; M E Lesch; F E Wincott; L Beigelman; S W Hunt; D J Schrier
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-23       Impact factor: 11.205

7.  Inhibition of expression of the multidrug resistance-associated P-glycoprotein of by phosphorothioate and 5' cholesterol-conjugated phosphorothioate antisense oligonucleotides.

Authors:  S K Alahari; N M Dean; M H Fisher; R Delong; M Manoharan; K L Tivel; R L Juliano
Journal:  Mol Pharmacol       Date:  1996-10       Impact factor: 4.436

8.  Ribozyme modulation of lipopolysaccharide-induced tumor necrosis factor-alpha production by peritoneal cells in vitro and in vivo.

Authors:  M Sioud
Journal:  Eur J Immunol       Date:  1996-05       Impact factor: 5.532

9.  Synthesis and anti-HIV activity of thiocholesteryl-coupled phosphodiester antisense oligonucleotides incorporated into immunoliposomes.

Authors:  O Zelphati; E Wagner; L Leserman
Journal:  Antiviral Res       Date:  1994-09       Impact factor: 5.970

10.  Phosphorothioate hammerhead ribozymes targeting a conserved sequence in the V3 loop region inhibit HIV-1 entry.

Authors:  X Zhang; Y Iwatani; T Shimayama; R Yamada; A Koito; Y Xu; H Sakai; T Uchiyama; T Hattori
Journal:  Antisense Nucleic Acid Drug Dev       Date:  1998-12
View more
  3 in total

1.  Secondary structure prediction and in vitro accessibility of mRNA as tools in the selection of target sites for ribozymes.

Authors:  M Amarzguioui; G Brede; E Babaie; M Grotli; B Sproat; H Prydz
Journal:  Nucleic Acids Res       Date:  2000-11-01       Impact factor: 16.971

2.  HIV-1 LTR as a target for synthetic ribozyme-mediated inhibition of gene expression: site selection and inhibition in cell culture.

Authors:  B Bramlage; E Luzi; F Eckstein
Journal:  Nucleic Acids Res       Date:  2000-11-01       Impact factor: 16.971

3.  Delta ribozyme benefits from a good stability in vitro that becomes outstanding in vivo.

Authors:  Dominique Lévesque; Sanaa Choufani; Jean-Pierre Perreault
Journal:  RNA       Date:  2002-04       Impact factor: 4.942

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.